Nippon Shinyaku Co Ltd banner
N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 5 021 JPY 0.58% Market Closed
Market Cap: ¥352.7B

Nippon Shinyaku Co Ltd
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Nippon Shinyaku Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
N
Nippon Shinyaku Co Ltd
TSE:4516
Total Receivables
¥53.7B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
3%
Takeda Pharmaceutical Co Ltd
TSE:4502
Total Receivables
¥757.9B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
4%
Daiichi Sankyo Co Ltd
TSE:4568
Total Receivables
¥696B
CAGR 3-Years
25%
CAGR 5-Years
21%
CAGR 10-Years
9%
Otsuka Holdings Co Ltd
TSE:4578
Total Receivables
¥570.3B
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Total Receivables
¥443.1B
CAGR 3-Years
-5%
CAGR 5-Years
12%
CAGR 10-Years
11%
Astellas Pharma Inc
TSE:4503
Total Receivables
¥792.1B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
8%
No Stocks Found

Nippon Shinyaku Co Ltd
Glance View

Market Cap
352.7B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Intrinsic Value
4 976.33 JPY
Overvaluation 1%
Intrinsic Value
Price ¥5 021
N

See Also

What is Nippon Shinyaku Co Ltd's Total Receivables?
Total Receivables
53.7B JPY

Based on the financial report for Dec 31, 2025, Nippon Shinyaku Co Ltd's Total Receivables amounts to 53.7B JPY.

What is Nippon Shinyaku Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
3%

Over the last year, the Total Receivables growth was 6%. The average annual Total Receivables growth rates for Nippon Shinyaku Co Ltd have been 1% over the past three years , 2% over the past five years , and 3% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett